Wednesday, February 22, 2012

As for the h041, the voltage is in japan...

New, incurable stress, sexually transmitted disease gonorrhea was found in Japan, according to an international group of experts of infectious diseases. Strain strattera 40mg, named H041, resistant to all known antibiotics forms. Similar results were presented on Monday with a large laboratory evidence at a conference in Quebec, Canada - and it comes just three days after the Center for Disease Control and Prevention (CDC) warned that the U.S. samples gonorrhea was time to show new signs of resistance drugs as well. Although drugs are effective in almost all cases, the U.S., CDC noted that the analysis of samples of bacteria from 2000 to 2010 showed that gonorrhea error becomes less and less susceptible to frontline drugs cephalosporins, as over the years. This disturbing and predictable discoveries, Dr. Magnus Unemo said. Unemo, based on Swedish reference laboratory for pathogenic Neisseria, working with Japanese colleagues to describe the new H041 multidrug-resistant gonorrhea strain. Multidrug resistance is predictable, according Unemos, because most strains of gonorrhea in the world is stable, at least one major class of antibiotics. Bacteria become resistant to antibiotics in the process of evolution. Some natural genetic variation exists in the


3 beneficial effects of bacteria

gonococci, bacterial organism that causes gonorrhea, which means that any of this bacterium may, by chance, be a little more sensitive to antibiotics than the other. When a colony of bacteria, first comes into contact with antibiotics because antibiotics kill the bacteria most sensitive at higher rates. It reserves the disproportionately strong party surviving bacteria, and when the survivors reproduce, they are more reliable than the average genes to their descendants. With repeated exposure to antibiotics, and for many generations of bacteria, eventually all the bacteria that is spread drug-resistant. In the U.S., gonorrhea strains resistant to penicillin and tetracycline have been circulating since 1970 and is widely spread in the early 1980's, according to CDC. Since most of


gonococci also become resistant to fluoroquinolines, today CDC recommends treating gonorrhea with cephalosporins and azithromycin or doxycycline or (two relatively frequently administered antibiotics). But the latter means that some American examples


gonococci are no longer responsible just as good as it used to cephalosporins or - bacteria are less susceptible - and now a new strain in Japan, reportedly resistant to everything. This brings us to what the researcher called Magnus Unemo alarming. Gonorrhea is by no means the most dangerous sexually transmitted diseases. But this is one of the most popular - with 700,000 new cases in the U.S. each year and about 340 million new cases annually worldwide. Painful sexual intercourse (in women), tender and swollen testicles (in men), and pain during urination (among infected people of both sexes). If untreated, gonorrhea can lead to internal scarring of the genital tract, and in women, pelvic inflammatory disease or infertility life. Possibility of honokokkovoy cephalosporin resistance is of particular concern because the U.S. gonorrhea control strategy based on effective antibiotic therapy, CDC announced on Friday. No other well-studied and effective treatment with antibiotics or combinations of them are now [only bacteria resistant to cephalosporins]. As for the H041, the voltage is in Japan: It is still too early to assess if this new strain is widespread, the history of emerging resistance in bacteria that it can spread rapidly if new medicines and effective treatment program is developed, Unemo said in his statement. In fact, when researchers increased with drug-resistant bacteria in the culture of other strains of gonorrhea, the new strain was able to transfer its resistance rapidly, increasing the resistance of other strains to cephalosporins, about 500 times. This suggests that H041 can spread quickly and resistance in the real world. .

No comments:

Post a Comment